HomeProductsBioactive CompoundsProtein Kinase TargetsPDGFRVorolanib
Chemical structure of CAS 1013920-15-4

Vorolanib

In Stock•Starting at $228 for 5 mg•Purity ≥ 98%
CAS No.1013920-15-4
MDL No.N/A
MFC23H26FN5O3
MW439.50
InChI KeyKMIOJWCYOHBUJS-HAKPAVFJSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg98%$228In Stock
10 mg98%$366In Stock
25 mg98%$655In Stock
50 mg98%$1181In Stock
100 mg98%$1675In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1013920-15-4
Product NameVorolanib

Associated Conditions

age-related macular degeneration·small cell lung carcinoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo.

Microvascular research • Vol. 136 • 2021
PMID: 33610563DOI: 10.1016/j.mvr.2021.104146

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu • Vol. 33, Issue 1 • 2021
PMID: 33707933PMC: PMC7941683DOI: 10.21147/j.issn.1000-9604.2021.01.11

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.

EBioMedicine • Vol. 55 • 2020
PMID: 32335374PMC: PMC7184160DOI: 10.1016/j.ebiom.2020.102755

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats.

Journal of ophthalmology • Vol. 2017 • 2017
PMID: 29201457PMC: PMC5671735DOI: 10.1155/2017/6145651

Documentation

Similar Products